What Happened

Sandoz CEO Richard Saynor warned that Trump's proposed tariffs on generic drugs could force manufacturers to raise prices or stop supplying certain medicines, impacting U.S. patients. Sandoz also announced plans to double net sales by 2035 and expand its biosimilar portfolio.

Who Is Affected

U.S. patients relying on affordable generic drugs could face higher prices or reduced availability. Generic drug manufacturers like Sandoz may need to adjust pricing strategies or exit certain markets.

Market Impact

• Tariffs could disrupt the supply chain for generic drugs, which account for 90% of U.S. prescriptions.
• Sandoz aims to capitalize on patent expirations, particularly in immunology and oncology, creating opportunities for biosimilar competition.
• The company plans to target 80% of the value of biologic drugs losing patent protection by 2035.

What to Watch

Monitor Sandoz's progress in securing approvals for biosimilars like generic semaglutide and its ability to meet ambitious growth targets. Also, track regulatory developments around Trump's proposed tariffs and their potential implementation.

Related coverage

• FDA approves eGenesis pig liver trial for acute liver failure treatment
• FDA approves Revolution Medicines' daraxonrasib for advanced pancreatic cancer
• FDA Accepts NDA for Apnimed's Sleep Apnea Pill AD109
• Longeveron's Laromestrocel reduces neuroinflammation in Alzheimer's patients